Trial site
Woman's Hospital
Baton Rouge, Louisiana 70817, United StatesNot linked to an institution yet
- 15running trials
- 5closed trials
The trials here
What the 20 trials at this site are about, from their registry records.
- Phase
- Phase 311 trials
- Phase 2/32 trials
- Phase 1/21 trial
- Phase 41 trial
- Status
- Active, not recruiting11 trials
- Completed4 trials
- Recruiting4 trials
- Terminated1 trial
- Lead sponsor
- National Cancer Institute (NCI)9 trials
- Alliance for Clinical Trials in Oncology2 trials
- NRG Oncology2 trials
- Teal Health, Inc.2 trials
- BillionToOne Inc.1 trial
- and 4 more
Running trials
Recruiting
Advancing Stillbirth Prevention Through Innovative Risk Evaluation (ASPIRE) Clinical Study
NCT07669935· Medicines360· Source
Contact: Elizabeth Sutton
Recruiting
The ADVANCE (Assay Development and Validation for Pre-Natal and Obstetric Conditions) Study is the Largest U.S.-Based Prospective Study Demonstrating a Circulating Fetal Cell (CFC) Based Approach to Non-invasive Fetal Risk Assessment
NCT07643896· BillionToOne Inc.· Source
Contact: Bri Jones, MPH
Active, not recruiting
SELF-CERV Pivotal Study: SELF-Collection for CERVical Cancer Screening
NCT06120205· Teal Health, Inc.· Source
Active, not recruiting
Development of a Self-collection Device for Cervical Cancer Screening
NCT05669911· Teal Health, Inc.· Source
Recruiting
Treatment to Regress to Normoglycemia in Women with a Recent History of GDM
NCT04873050· Phase 4· Woman's· Source
Contact: Elizabeth Sutton, PhD
Active, not recruiting
NCI COVID-19 in Cancer Patients, NCCAPS Study
NCT04387656· National Cancer Institute (NCI)· Source
Active, not recruiting
Single Fraction Stereotactic Radiosurgery or Three to Five Fraction Stereotactic Radiosurgery in Treating Patients With Brain Metastasis That Has Been Removed by Surgery
NCT04114981· Phase 3· Alliance for Clinical Trials in Oncology· Source
Active, not recruiting
Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer
NCT03914612· Phase 3· National Cancer Institute (NCI)· Source
Recruiting
S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity
NCT03418961· Phase 3· SWOG Cancer Research Network· Source
Contact: Victor T. Lin (principal investigator)
Active, not recruiting
Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer
NCT02954874· Phase 3· National Cancer Institute (NCI)· Source
Active, not recruiting
Breast Cancer WEight Loss Study (BWEL Study)
NCT02750826· Phase 3· Alliance for Clinical Trials in Oncology· Source
Active, not recruiting
Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer
NCT02502266· Phase 2/3· National Cancer Institute (NCI)· Source
Active, not recruiting
Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NCT02446600· Phase 3· National Cancer Institute (NCI)· Source
Active, not recruiting
Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer
NCT02488967· Phase 3· NRG Oncology· Source
Active, not recruiting
Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer
NCT00565851· Phase 3· National Cancer Institute (NCI)· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error